Search Results - "Montheard, Sandrine"

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study by Abramson, Jeremy S., Solomon, Scott R., Arnason, Jon, Johnston, Patrick B., Glass, Bertram, Bachanova, Veronika, Ibrahimi, Sami, Mielke, Stephan, Mutsaers, Pim, Hernandez-Ilizaliturri, Francisco, Izutsu, Koji, Morschhauser, Franck, Lunning, Matthew, Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro, Ogasawara, Ken, Kamdar, Manali

“…•Liso-cel significantly improved EFS, CR rate, and PFS vs chemotherapy ± ASCT as a second-line treatment for LBCL.•Liso-cel was well tolerated as a second-line…”
Get full text

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial by Kamdar, Manali, Solomon, Scott R, Arnason, Jon, Johnston, Patrick B, Glass, Bertram, Bachanova, Veronika, Ibrahimi, Sami, Mielke, Stephan, Mutsaers, Pim, Hernandez-Ilizaliturri, Francisco, Izutsu, Koji, Morschhauser, Franck, Lunning, Matthew, Maloney, David G, Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro, Stepan, Lara, Ogasawara, Ken, Mack, Timothy, Abramson, Jeremy S

“…Patients with large B-cell lymphoma (LBCL) primary refractory to or relapsed within 12 months of first-line therapy are at high risk for poor outcomes with…”
Get full text

Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Compared with Standard of Care (SOC) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study by Abramson, Jeremy S., Solomon, Scott R., Arnason, Jon E., Johnston, Patrick B., Glass, Bertram, Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro, Liu, Fei Fei, Braverman, Julia, Guo, Shien, Shi, Ling, Kamdar, Manali

“…Background: Pts with previously treated R/R aggressive LBCL have compromised health-related QOL (HRQOL). Liso-cel is an autologous, CD19-directed, defined…”
Get full text

Subgroup analyses of primary refractory (refr) vs early relapsed (rel) large B-cell lymphoma (LBCL) from the TRANSFORM study of lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) as second-line (2L) therapy by Nastoupil, Loretta J., Kamdar, Manali K., Chavez, Julio C., Ghesquieres, Herve, Ghosh, Monalisa, Holmes, Houston, López Guillermo, Armando, Martinez-Lopez, Joaquin, Novak, Urban, Ribrag, Vincent, Roddie, Claire, Waller, Edmund K., Feldman, Tatyana A, Rosenthal, Allison Claire, Sauter, Craig, Von Bonin, Malte, Karmali, Reem, Montheard, Sandrine, Previtali, Alessandro, Abramson, Jeremy S.

“…7526 Background: The TRANSFORM primary analysis (PA; NCT03575351) confirmed the superior efficacy of liso-cel vs SOC as 2L therapy in patients (pts) with…”
Get full text

Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study by Kamdar, Manali, Solomon, Scott R., Arnason, Jon E., Johnston, Patrick B., Glass, Bertram, Bachanova, Veronika, Ibrahimi, Sami, Mielke, Stephan, Mutsaers, Pim G.N.J., Hernandez-Ilizaliturri, Francisco J., Izutsu, Koji, Morschhauser, Franck, Lunning, Matthew A., Maloney, David G., Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro, Stepan, Lara, Ogasawara, Ken, Mack, Timothy, Abramson, Jeremy S.

“…▪ Background: Pts with LBCL primary refractory to or relapsed ≤ 12 mo after first-line (1L) therapy may have poor outcomes with SOC, including salvage CT and…”
Get full text

Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 Transform Study by Abramson, Jeremy S., Solomon, Scott R., Arnason, Jon E., Johnston, Patrick B., Glass, Bertram, Bachanova, Veronika, Ibrahimi, Sami, Mielke, Stephan, Mutsaers, Pim, Hernandez-Ilizaliturri, Francisco, Izutsu, Koji, Morschhauser, Franck, Lunning, Matthew A., Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro, Kamdar, Manali

Get full text

Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen by Abramson, Jeremy S, Solomon, Scott R, Arnason, Jon, Johnston, Patrick B, Glass, Bertram, Bachanova, Veronika, Ibrahimi, Sami, Mielke, Stephan, Mutsaers, Pim, Hernandez-Ilizaliturri, Francisco, Izutsu, Koji, Morschhauser, Franck, Lunning, Matthew, Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro, Ogasawara, Ken, Kamdar, Manali

Get more information

Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL by Abramson, Jeremy S., Johnston, Patrick B., Kamdar, Manali, Ibrahimi, Sami, Izutsu, Koji, Arnason, Jon, Glass, Bertram, Mutsaers, Pim, Lunning, Matthew, Braverman, Julia, Liu, Fei Fei, Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro, Guo, Shien, Shi, Ling, Solomon, Scott R.

“…•In TRANSFORM, health-related quality of life improved or was maintained with second-line lisocabtagene maraleucel vs standard of care.•HRQOL results coupled…”
Get full text

232 - Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor T Cell Therapy, Compared with Standard of Care (SOC) Using Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study by Abramson, Jeremy S., Solomon, Scott R., Arnason, Jon E., Johnston, Patrick B, Glass, Bertram, Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro, Liu, Fei Fei, Braverman, Julia, Guo, Shien, Shi, Ling, Kamdar, Manali

Get full text

Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor T Cell Therapy, Compared with Standard of Care (SOC) Using Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study by Abramson, Jeremy S., Solomon, Scott R., Arnason, Jon E., Johnston, Patrick B, Glass, Bertram, Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro, Liu, Fei Fei, Braverman, Julia, Guo, Shien, Shi, Ling, Kamdar, Manali

Get full text

44 - Primary Analysis (PA) Results from the Randomized, Phase 3 TRANSFORM Study of Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) by Abramson, Jeremy S., Solomon, Scott R., Arnason, Jon, Johnston, Patrick B., Glass, Bertram, Bachanova, Veronika, Ibrahimi, Sami, Mielke, Stephan, Mutsaers, Pim, Hernandez-Ilizaliturri, Francisco, Izutsu, Koji, Morschhauser, Franck, Lunning, Matthew, Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro, Stepan, Lara, Ogasawara, Ken, Kamdar, Manali

Get full text

Primary Analysis (PA) Results from the Randomized, Phase 3 TRANSFORM Study of Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) by Abramson, Jeremy S., Solomon, Scott R., Arnason, Jon, Johnston, Patrick B., Glass, Bertram, Bachanova, Veronika, Ibrahimi, Sami, Mielke, Stephan, Mutsaers, Pim, Hernandez-Ilizaliturri, Francisco, Izutsu, Koji, Morschhauser, Franck, Lunning, Matthew, Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro, Stepan, Lara, Ogasawara, Ken, Kamdar, Manali

Get full text

66 - Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study by Kamdar, Manali, Solomon, Scott R., Arnason, Jon E., Johnston, Patrick B, Glass, Bertram, Bachanova, Veronika, Ibrahimi, Sami, Mielke, Stephan, Mutsaers, Pim, Hernandez-Ilizaliturri, Francisco J, Izutsu, Koji, Morschhauser, Franck, Lunning, Matthew, Maloney, David G., Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro, Stepan, Lara, Ogasawara, Ken, Mack, Timothy, Abramson, Jeremy S.

Get full text

Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study by Kamdar, Manali, Solomon, Scott R., Arnason, Jon E., Johnston, Patrick B, Glass, Bertram, Bachanova, Veronika, Ibrahimi, Sami, Mielke, Stephan, Mutsaers, Pim, Hernandez-Ilizaliturri, Francisco J, Izutsu, Koji, Morschhauser, Franck, Lunning, Matthew, Maloney, David G., Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro, Stepan, Lara, Ogasawara, Ken, Mack, Timothy, Abramson, Jeremy S.

Get full text